Wegovy 1.7mg FlexTouch

Wegovy 1.7 mg FlexTouch – Semaglutide Injection for Weight Management

Wegovy 1.7 mg FlexTouch is a prescription pre-filled injection pen containing Semaglutide. It is used together with a reduced-calorie diet and increased physical activity to support long-term weight management in eligible individuals. Semaglutide belongs to a group of medicines known as glucagon-like peptide-1 receptor agonists, also called GLP-1 receptor agonists. It acts on brain regions involved in appetite regulation, helping to reduce hunger, increase feelings of fullness, and support reduced food intake. Each Wegovy weight loss FlexTouch pen contains 6.8 mg of semaglutide in 3 mL and provides 4 separate 1.7 mg doses. This strength is generally used during dose escalation and should not be started unless prescribed by a qualified healthcare professional.

Key Features

• Contains Semaglutide: A once-weekly GLP-1 receptor agonist.
• 1.7 mg Per Dose: Each multidose pen provides four doses of 1.7 mg.
• Supports Weight Management: Helps regulate appetite and reduce food intake.
• Once-Weekly Administration: Designed for use on the same day each week.
• FlexTouch Pre-Filled Pen: Provides convenient subcutaneous administration.
• Prescription Medicine: Must be used as part of a medically supervised treatment programme.

Active Ingredient

• Semaglutide 1.7 mg per dose: A GLP-1 receptor agonist that helps regulate appetite, increase fullness, and support reduced calorie intake.

Uses

• Long-term weight management in eligible adults with obesity.
• Weight management in eligible adults who are overweight and have at least one weight-related health condition.
• Weight management in eligible adolescents aged 12 years and above with obesity, where approved and prescribed.
• Supports weight loss and maintenance when combined with a reduced-calorie diet and regular physical activity.

How to Use

• Use Wegovy 1.7 mg FlexTouch exactly as your healthcare professional prescribes.
• Inject it once weekly on the same day each week.
• You may use it at any time of day, with or without food.
• Inject the prescribed dose under the skin of the abdomen, thigh, or upper arm.
• Do not inject it into a vein or muscle.
• Rotate the injection area regularly and avoid injecting repeatedly into the same spot.
• Attach a new compatible disposable needle before every injection.
• Check that the solution is clear and colourless before use.
• Remove and safely discard the needle immediately after each injection.
• Never share the pen or needles with another person.

Precautions

• Contact a healthcare professional if severe nausea, vomiting, or diarrhoea causes dehydration.
• People using insulin or sulfonylurea medicines may have an increased risk of low blood sugar.
• Inform your doctor if you have diabetes-related eye disease or notice sudden vision changes.
• Inform medical professionals that you use semaglutide before surgery or a procedure involving general anaesthesia or deep sedation.
• Do not use Wegovy together with another semaglutide medicine or another GLP-1 receptor agonist unless specifically directed.
• Seek immediate medical assistance for facial swelling, breathing difficulty, severe rash, or another serious allergic reaction.

Possible Side Effects

• Nausea.
• Vomiting.
• Diarrhoea.
• Constipation.
• Abdominal pain or discomfort.
• Indigestion, bloating, or acid reflux.
• Headache.
• Dizziness.
• Fatigue or weakness.
• Injection-site reactions.
• Gallstones or gallbladder inflammation.

Storage

• Before first use, store in a refrigerator between 2°C and 8°C.
• Keep the pen away from the refrigerator’s cooling element.
• Do not freeze and do not use a pen that has been frozen.
• After first use, store below 30°C or preferably in a refrigerator between 2°C and 8°C.
• Keep the pen cap attached when it is not being used to protect the medicine from light.
• Do not store the pen with a needle attached.
• Keep out of reach of children and unauthorized individuals.

Legal Disclaimer: Wegovy 1.7 mg FlexTouch is a prescription medicine intended for use under the supervision of a qualified healthcare professional. It is not a starting dose and may cause serious adverse reactions. Eligibility, dose escalation, treatment duration, and ongoing use must be determined by the prescribing doctor. This information is provided for educational purposes only and should not replace professional medical advice, diagnosis, treatment, or the official instructions supplied with the medicine.